KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Xenon Pharmaceuticals (XENE) over the last 11 years, with Q1 2025 value amounting to 969.84%.

  • Xenon Pharmaceuticals' EBIT Margin changed N/A to 969.84% in Q1 2025 from the same period last year, while for Sep 2025 it was 4543.73%, marking a year-over-year change of. This contributed to the annual value of 1368.91% for FY2022, which is 9404600.0% down from last year.
  • As of Q1 2025, Xenon Pharmaceuticals' EBIT Margin stood at 969.84%.
  • In the past 5 years, Xenon Pharmaceuticals' EBIT Margin ranged from a high of 198.14% in Q1 2022 and a low of 28884.85% during Q3 2022
  • Moreover, its 3-year median value for EBIT Margin was 817.25% (2021), whereas its average is 4762.84%.
  • The largest annual percentage gain for Xenon Pharmaceuticals' EBIT Margin in the last 5 years was 1703500bps (2022), contrasted with its biggest fall of -285382300bps (2022).
  • Over the past 3 years, Xenon Pharmaceuticals' EBIT Margin (Quarter) stood at 664.65% in 2021, then crashed by -4246bps to 28884.85% in 2022, then soared by 97bps to 969.84% in 2025.
  • Its last three reported values are 969.84% in Q1 2025, 28884.85% for Q3 2022, and 5655.78% during Q2 2022.